Default DAPT Duration ≥ 12 Months Post ACS Strategy Tool

Default dual antiplatelet therapy duration ≥ twelve months after acute coronary syndrome strategy tool explanation and clinical context Dual antiplatelet therapy which combines aspirin with an oral P two Y twelve inhibitor is a cornerstone of treatment after acute coronary syndrome because it lowers the risk of early and late thrombotic events including recurrent myocardial infarction and stent thrombosis across both ST segment elevation and non ST segment elevation presentations. Large trials such as CURE and those testing prasugrel and ticagrelor demonstrated that one year of dual antiplatelet therapy reduces major adverse cardiovascular events compared with aspirin alone at the cost of higher bleeding risk. In the twenty twenty five American College of Cardiology and American Heart Association guideline for acute coronary syndrome the default recommendation for patients who are not at high bleeding risk is to continue dual antiplatelet therapy with aspirin and an oral P two Y twelve inhibitor for at least twelve months after the index event.

Ticagrelor or prasugrel is preferred over clopidogrel in patients who undergo percutaneous coronary intervention while ticagrelor or clopidogrel is used in patients managed without routine percutaneous coronary intervention. The same guideline underscores that this default plan applies mainly to patients without high bleeding risk. In those who meet high bleeding risk criteria or who require chronic oral anticoagulant therapy abbreviated dual antiplatelet therapy regimens and alternative strategies are advised including early transition to ticagrelor monotherapy or to single antiplatelet therapy after the first month in selected patients and early discontinuation of aspirin in patients who need oral anticoagulant therapy.

Multiple risk scores and consensus criteria such as the Academic Research Consortium high bleeding risk definition help clinicians identify patients who are likely to benefit from deviation away from a full twelve month course of standard dual antiplatelet therapy. This tool does not calculate a numerical risk score but instead synthesizes key information about bleeding risk the need for oral anticoagulant therapy the initial treatment approach to acute coronary syndrome and early treatment tolerance in order to show whether a patient fits the default strategy of dual antiplatelet therapy for at least twelve months or whether the guideline suggests shortened or modified antiplatelet regimens. It is intended for educational and documentation support only and should always be used alongside comprehensive clinical judgment formal risk assessment shared decision making with the patient and up to date guidance from professional society recommendations.